Immune checkpoint inhibitors (ICI) and other antineoplastic treatment regimens can trigger cutaneous immune-related adverse events (irAEs). There is a tendency for underreporting of such cases, as irAEs are typically perceived mild transient. However, more serious occur which, despite their lower frequency, deserve attention require specific care. Here, we report case extensive hyperpigmented s...

A 40-year-old man with a diagnosis of lung adenocarcinoma (cT4N3M1c, stage IVB) experienced worsening of lymphangitic carcinomatosis in the right lung and right pleural effusion after receiving 1 cycle of first-line chemotherapy consisting of cisplatin and pemetrexed. Bevacizumab was thus added from the second cycle of the cisplatin-pemetrexed regimen, leading to a marked improvement in pulmona...

BACKGROUND AND OBJECTIVE The aim of this study is to integrate with literature review, and explore the value of treatment of advanced non-small cell lung cancer with second line. METHODS For the metastatic progressive non-small cell lung adenocarcinoma patient, the evaluation of efficacy for complete response (CR) with endostar combined GC, the sequential treatment with gefitinib, used pemetr...

We report a patient with unknown primary undifferentiated carcinoma who developed acute renal failure associated with interstitial fibrosis following pemetrexed therapy. Despite drug withdrawal, renal function remained altered and the patient experienced chronic renal insufficiency. Pemetrexed disodium (Alimta) is a multitargeted antifolate agent approved by the Food and Drug Administration (FD...

Clinical Practice Points Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKþ tumors have a longer progr...

BACKGROUND The aim of this study was to determine the progression-free survival (PFS) and toxicity associated with adjuvant administration of carboplatin and pemetrexed for completely resected patients with stage IB, II and IIIA non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Forty-five eligible NSCLC patients received surgical resection for pathological stage IB, II or IIIA followed...

OBJECTIVE Current regulatory guidelines advise 5-7 days of folic acid supplementation prior to pemetrexed. Although taking folic acid during and after pemetrexed therapy is important, it remains unclear whether premedication is truly necessary, particularly as it can be inconvenient for patients, can contribute to their anxiety by delaying chemotherapy, and can create challenges in scheduling c...

INTRODUCTION BIBF 1120 (planned brand name Vargatef) is a novel, oral, triple angiokinase inhibitor targeting three receptor classes involved in blood vessel formation. The objectives of this phase I, open-label dose-escalation study were to determine the safety, tolerability, and maximum tolerated dose (MTD) of BIBF 1120 with pemetrexed in patients with recurrent advanced-stage non-small cell ...

PURPOSE Thymic malignancies are rare, with limited published trials of chemotherapy activity. We performed a retrospective analysis of pemetrexed activity in patients with thymic malignancies. METHODS Patients with unresectable histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma seen at the Stanford Cancer Center between January 2005 and November 2013 were ...

OBJECTIVE To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). METHODS An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NS...